Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of the NMF Biomarker as Predictive Diagnostic for Effective Use of Cyclosporine and Dupilumab in the Treatment of Atopic Dermatitis

NCT04878770 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT04878770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04878770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of the NMF Biomarker as Predictive Diagnostic for Effective Use of Cyclosporine and Dupilumab in the Treatment of Atopic Dermatitis
Lead sponsor
Erasmus Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
August 16, 2021
Completion date
January 1, 2025
Enrollment
318 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic